Crizanlizumab Suppliers & Bulk Manufacturers

Available Forms: IV Infusion

Available Strengths: 100 mg/10 mL (10 mg/mL)

Reference Brands: Adakveo®(EU & US)

Category: Anemia

Crizanlizumab (Adakveo®) is an FDA- and EMA-approved IV biologic for sickle cell disease, available for B2B pharma distribution in the US and EU to reduce pain crises in affected patients. Crizanlizumab is available in IV Infusion and strengths such as 100 mg/10 mL (10 mg/mL). Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Crizanlizumab is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Crizanlizumab can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

rizanlizumab (Adakveo®) is a breakthrough biologic therapy for sickle cell disease, available for B2B pharmaceutical distribution across the US and EU markets. It is a humanized monoclonal antibody (anti-P-selectin) used to reduce the frequency of painful vaso-occlusive crises in patients with sickle cell anemia. Approved by the FDA and EMA, Crizanlizumab is supplied as a 100 mg/10 mL IV infusion, ideal for hospital and specialty clinic use. Pharma B2B partners benefit from secure supply chains, regulatory-compliant sourcing, and access to one of the most innovative therapies in hematology. Reliable distribution and market-ready packaging ensure smooth commercialization across regulated markets.